These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35783619)

  • 1. CK5/6 and GATA3 Defined Phenotypes of Muscle-Invasive Bladder Cancer: Impact in Adjuvant Chemotherapy and Molecular Subtyping of Negative Cases.
    Koll FJ; Schwarz A; Köllermann J; Banek S; Kluth L; Wittler C; Bankov K; Döring C; Becker N; Chun FKH; Wild PJ; Reis H
    Front Med (Lausanne); 2022; 9():875142. PubMed ID: 35783619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.
    Bejrananda T; Kanjanapradit K; Saetang J; Sangkhathat S
    Sci Rep; 2021 Oct; 11(1):21186. PubMed ID: 34707176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16.
    Terlević R; Ulamec M; Štimac G; Murgić J; Krušlin B
    Biomol Biomed; 2023 Nov; 23(6):968-975. PubMed ID: 37389960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
    Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
    World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer.
    Koll FJ; Döring C; Herwig L; Hoeh B; Wenzel M; Cano Garcia C; Banek S; Kluth L; Köllermann J; Weigert A; Chun FK; Wild P; Reis H
    J Clin Pathol; 2024 Dec; 78(1):19-27. PubMed ID: 37989554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
    Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
    Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice.
    Queipo FJ; Unamunzaga GM; Negro BF; Fuertes SG; Cortés MÁ; Tejedor EC; Mañas CMB; Ariño AB; Sjödahl G; Beorlegui C
    Virchows Arch; 2022 Aug; 481(2):191-200. PubMed ID: 35731280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
    Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
    Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
    Ravanini JN; Assato AK; Wakamatsu A; Alves VAF
    Clinics (Sao Paulo); 2021; 76():e2587. PubMed ID: 33909826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
    Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
    PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.
    Wang CC; Tsai YC; Jeng YM
    PLoS One; 2019; 14(8):e0221785. PubMed ID: 31469885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
    Serag Eldien MM; Abdou AG; Elghrabawy GRA; Alhanafy AM; Mahmoud SF
    J Immunoassay Immunochem; 2021 Nov; 42(6):662-678. PubMed ID: 34106817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Features and Survival Analysis in Molecular Subtypes of Muscle-Invasive Bladder Cancer.
    Sanguedolce F; Falagario UG; Zanelli M; Palicelli A; Zizzo M; Ascani S; Tortorella S; Mancini V; Cormio A; Carrieri G; Cormio L
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.
    Benítez R; Yu K; Sirota M; Malats N; Pineda S
    Front Immunol; 2023; 14():986598. PubMed ID: 36817478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
    Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.
    Hesswani C; Jackson CL; Marcq G; Hardy C; Kool R; Mansure JJ; Brimo F; Berman DM; Kassouf W
    Eur Urol Open Sci; 2023 Nov; 57():22-29. PubMed ID: 38020525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
    Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
    Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.
    Groeneveld CS; Pfister C; Culine S; Harter V; Krucker C; Fontugne J; Dixon V; Sirab N; Bernard-Pierrot I; de Reyniès A; Radvanyi F; Allory Y;
    Ann Oncol; 2024 Sep; ():. PubMed ID: 39299443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
    Koll FJ; Döring C; Olah C; Szarvas T; Köllermann J; Hoeh B; Chun FK; Reis H; Wild PJ
    BMC Cancer; 2023 Jun; 23(1):504. PubMed ID: 37270477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.